Evidence map›Paper›PMID 36788184›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

A new border for circadian rhythm gene NFIL3 in diverse fields of cancer.

Lixuan Zeng, DongXin Chen, Yang Xue, Minghui Zhang, Yiqi Wu, Weiwei Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lixuan Zeng *Department of Pathology, Harbin Medical University, No. 157 Baojian Road, Harbin, 150086, Heilongjiang, People's Republic of China.
DongXin Chen *Department of Pathology, Harbin Medical University, No. 157 Baojian Road, Harbin, 150086, Heilongjiang, People's Republic of China.
Yang Xue *Department of Pathology, Harbin Medical University, No. 157 Baojian Road, Harbin, 150086, Heilongjiang, People's Republic of China.
Minghui Zhang *Department of Oncology, Chifeng City Hospital, Chifeng, 024000, China.
Yiqi WuDepartment of Pathology, Harbin Medical University, No. 157 Baojian Road, Harbin, 150086, Heilongjiang, People's Republic of China. lgwyq050724@163.com.
Weiwei YangDepartment of Pathology, Harbin Medical University, No. 157 Baojian Road, Harbin, 150086, Heilongjiang, People's Republic of China. yangweiwei113@163.com.ORCID http://orcid.org/0000-0002-3095-6607
Harbin Medical University · CNChifeng Municipal Hospital · CN

Funding

Natural Science Foundation of Heilongjiang Province of China LH2022H008Natural Science Foundation of Inner Mongolia 2020MS08084Postdoctoral Scientific Research Development Fund of Heilongjiang Province LBH-Q20046
6 · The paper itself

Abstract

The circadian rhythm disorder and abnormal expression of rhythm genes are related to many diseases, especially cancer. Rhythm gene NFIL3 is involved in energy metabolism and immune cell differentiation, and its aberrant expression is associated with metabolic diseases and inflammation. Previously, numerous studies have shown that aberrant NFIL3 expression is associated with tumorigenesis, progression, and chemotherapy resistance. For instance, NFIL3 performs as a nuclear transcription factor, impacts cell proliferation, represses apoptosis, and promotes cancer cell invasion and metastasis by regulating the transcription of target genes. In addition, NFIL3 expressed in cancer cells influences the type and proportion of infiltrated immune cells in the tumor microenvironment. Increased expression of NFIL3 induces the chemotherapy and immunotherapy resistance in cancer. In this review, we summarized the pathological functions of NFIL3 in tumorigenesis, cancer development, and treatment. The rhythm gene NFIL3 can be used as a promising target in cancer therapy in the future.

Indexed as

Basic-Leucine Zipper Transcription FactorsNeoplasmsCarcinogenesisCircadian RhythmGene Expression RegulationHumansTranscription FactorsTumor MicroenvironmentBasic-Leucine Zipper Transcription FactorsNFIL3 protein, humanTranscription FactorsCancer therapyNFIL3ProgressionRhythm genesTumorigenesis

Identifiers

PMID36788184
OpenAlexW4320855777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.